LIXTE BIOTECHNOLOGY HOLDINGS (LIXT)

Company Profile

Lixte Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company. The company is headquartered in East Setauket, New York and currently employs 3 full-time employees. The company went IPO on 2007-09-21. The Company’s product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers and encompasses two categories of compounds at various stages of pre-clinical and clinical development that has therapeutic potential not only for cancer but also for other debilitating and life-threatening diseases. The company is focused on development activities of its LB-100 series of drugs. The LB-100 series consists of novel structures, which treat not only several types of cancer but also vascular and metabolic diseases. The LB-200 series contains compounds, which has the potential to be effective in its class and may be useful for the treatment of chronic hereditary diseases.

Company Info

LIXTE BIOTECHNOLOGY HOLDINGS

No. 2, 248 Route 25A

East Setauket NEW YORK 11733

P: 13102032902

CEO: John S. Kovach

Employees: 3

Website: https://lixte.com/